Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 569 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR What to Know About Biomarker Testing for Lung Cancer: An Expert... June 9, 2022 Will Ponsegromab Be a Game Changer for Cancer Cachexia? October 17, 2024 Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... May 5, 2020 Load more HOT NEWS In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young...
